Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;8(10):1791-7.
doi: 10.2215/CJN.03140313. Epub 2013 Jun 6.

Re-envisioning Fistula First in a patient-centered culture

Affiliations

Re-envisioning Fistula First in a patient-centered culture

Amanda Gomes et al. Clin J Am Soc Nephrol. 2013 Oct.

Abstract

The main options for vascular access in hemodialysis patients are arteriovenous fistulas (AVFs), arteriovenous grafts, and tunneled cuffed central venous catheters. AVFs have the lowest complication rate and require the fewest interventions and lowest cost to maintain. There has been a dramatic national increase in prevalent AVFs among patients with ESRD in the United States driven, in part, by the Fistula First Breakthrough Initiative. The Fistula First Breakthrough Initiative has engaged stakeholders in the dialysis community to disseminate best practices and quality improvement activities to increase AVF prevalence in suitable candidates. In the pursuit of maximizing AVF placement and prevalence, less emphasis has been placed on the individual patient context. An AVF may not be the best access choice in a subset of patients, particularly those with poor long-term prognoses or comorbid chronic diseases with a short life expectancy, those patients more likely to die than to have their CKD progress to ESRD requiring dialysis, and those with vascular anatomy not amenable to successful AVF placement. Placement of an AVF in these patients subjects them to uncomfortable and likely unnecessary and/or unsuccessful surgeries at an expense, while doing little to improve their clinical outcome or their individual experience of care. AVF prevalence as a pay-for-performance measure without the appropriate case-mix adjustment may penalize providers for accepting higher-risk patients. Although a functioning AVF that provides reliable hemodialysis remains the gold standard for vascular access for most patients, it may not be the most suitable option for every patient.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Vascular access prevalence in the United States. CVC, tunneled cuffed central venous catheter. Reprinted from Fistula First Breakthrough Initiative: Fistula First Data. Available at: http://www.fistulafirst.org/AboutFistulaFirst/FFBIData.aspx. Accessed May 22, 2013.
Figure 2.
Figure 2.
Patient-centered vascular access assessment. AVG, arteriovenous graft; AVF, arteriovenous fistula. *Presumes prognosis acceptable and vascular anatomy criteria met. **Presumes end-of-life care discussions have taken place.

References

    1. Schild AF, Perez E, Gillaspie E, Seaver C, Livingstone J, Thibonnier A: Arteriovenous fistulae vs. arteriovenous grafts: A retrospective review of 1,700 consecutive vascular access cases. J Vasc Access 9: 231–235, 2008 - PubMed
    1. Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ, Pisoni RL: Vascular access use and outcomes: An international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 23: 3219–3226, 2008 - PMC - PubMed
    1. Couchoud C, Labeeuw M, Moranne O, Allot V, Esnault V, Frimat L, Stengel B, French Renal Epidemiology and Information Network (REIN) registry : A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant 24: 1553–1561, 2009 - PMC - PubMed
    1. Singh AK: ESAs in dialysis patients: Are you a hedgehog or a fox? J Am Soc Nephrol 21: 543–546, 2010 - PubMed
    1. Kliger AS, Fishbane S, Finkelstein FO: Erythropoietic stimulating agents and quality of a patient’s life: Individualizing anemia treatment. Clin J Am Soc Nephrol 7: 354–357, 2012 - PubMed